Antitumor Activity of Interleukin-1α and Cisplatin in a Murine Model System

Archives of Otolaryngology--Head and Neck Surgery

Volumn 121, Issue 2, 1995, Pages 197-200

  Grandis, Jennifer Rubin ^a   Chang, Ming Jei ^a   Yu, Wei Dong ^a   Johnson, Candace S ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; RECOMBINANT INTERLEUKIN 1ALPHA;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

ANIMAL; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; HEMORRHAGE; INTERLEUKIN-1; MICE; MICE, INBRED C3H; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0028814415     PISSN: 08864470     EISSN: 1538361X     Source Type: Journal    
DOI: 10.1001/archotol.1995.01890020059012     Document Type: Article

References (27)

1. Gery I, Gershon RK, Waksman BH. Potentiation of the T-Iymphocyte response to mitogens, I: the responding cell. J Exp Med. 1972;136:128-142.
2. Dinarello CA. Interleukin-1. Rev Infect Dis. 1984;6:51-95.
3. Le J, Vilcek J. Tumor necrosis factor and interleukin-1: cytokines with multiple overlapping biological activities. Lab Invest. 1987;56:234-248.
4. Smith KA, Lachman LB, Oppenheim JJ, Favata MJ. The functional relationship of the interleukins. J Exp Med. 1980;151:1551-1556.
5. Onozaki K, Matsushima K, Aggarwal BB, Oppenheim JJ. Human interleukin-1 is a cytocidal factor for several tumor cell lines. J Immunol. 1985;135:3962-3968.
6. Yoshioka K, Fuji A, Tahara H, Arao M, Kakumu S. Recombinant human interleukin-1 alpha is cytotoxic for and increases surface expression of HLA-A,B,C antigens of a human hepatoma cell line, PLC/PRF/5. Immunobiology. 1989; 178:380-389.
7. Braunschweiger PG, Johnson CS, Kumar N, Ord V, Furmanski P. Antitumor effects of recombinant human interleukin-1α in RIF-1 and Panc02 solid tumors. Cancer Res. 1988;48:6011-6016.
8. Constantinidis I, Braunschweiger PG, Wehrle JD, et al. 31P studies of the effect of recombinant human interleukin-1α on the bioenergetics of RIF-1 tumors. Cancer Res. 1989;49:6379-6382.
9. Braunschweiger PG. Kumar N, Constantinidis I, et al. Potentiation of interleukin-1α mediated anti-tumor effects by ketoconazole. Cancer Res. 1990;50: 4709-4717.
10. Braunschweiger PG, Johnson CS, Kumar N, Ord V, Furmanski P. The effect of adrenalectomy and dexamethasone on interleukin-1α induced responses in RIF-1 tumors. Br J Cancer. 1990;61:9-13.
11. Johnson CS, Chang MJ, Braunschweiger PG, Furmanski P. Acute hemorrhagic necrosis of tumors induced by interleukin-1α: effects independent of tumor necrosis factor. J Natl Cancer Inst. 1991;83:842-848.
12. Braunschweiger PG, Jones SA, Johnson CS, Furmanski P. Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin-1α. Cancer Res. 1991;51:5454-5460.
13. Johnson CS, Vlock DR, Chang MJ, Yu WD, Furmanski P, Johnson CS. Synergistic enhancement of cisplatin (cDDP) mediated anti-tumor activity by interleukin-1α (IL-1α) in C3H/HeJ RIF-1 tumors. Cancer Chemother Pharmacol. 1993;32:339-346.
14. Johnson JT, Myers EN, Schramm VL, et al. Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Cancer Res. 1987;60:301-311.
15. Fu KK, Rayner PA, Lam KN. Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion. Intervent Radiat Oncol Biol Physiol. 1984;10:1473-1478.
16. Braunschweiger PG, Pwlakos L, Schiffer LM. Cell kinetics in vivo and in vitro for C3H/HeJ spontaneous mammary tumors. J Natl Cancer Inst. 1977;59: 1197-1204.
17. Peterson HI, Appelgren L, Kjartansson I, Selander D. Vascular and extravascular spaces in a transplantable rat tumour after local x-ray irradiation. Cancer Res Clin Oncol. 1976;87:17-25.
18. Kaye J, Porcelli S, Tite J, Jones B, Janeway CA. Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells. J Exp Med. 1983;158:836-856.
19. Vlock DR, Johnson JT, Myers EN, et al. Preliminary trial of nonrecombinant interferon alpha in recurrent squamous cell carcinoma of the head and neck. Head Neck. 1991;13:749.
20. Usui N, Mimnaigh EG, Sinha BK. Synergistic antitumor activity of etoposide and human interleukin-1α against human melanoma cells. J Natl Cancer Inst. 1989;81:1904-1909.
21. Roberts JJ, Thomson AJ. The mechanisms of action of antitumor platinum compounds. Prog Nucleic Acid Res Mol Biol. 1979;22:71-133.
22. Oppenheim JJ, Kovacs EJ, Matsushima K, Durum SK. There is more than one interleukin-1. Immunol Today. 1986;7:45-56.
23. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev. 1990; 70:427-451.
24. Nachman RL, Hajjar KA, Silverstein RL, Dinarello CA. Interleukin-1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med. 1986; 163:1595-1600.
25. Smith JW, Urba W, Steis R, et al. Interleukin-1 alpha (IL-1α) results of a phase I toxicity and immunodulatory trial. Proc Am Soc Clin Oncol. 1990;9:186.
26. Crown J, Jakubowski A, Kemeny N, et al. A phase I trial of recombinant human interleukin-1α alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood. 1991;78:1420-1427.
27. Smith JW, Urba WJ, Curti BD, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol. 1992;10:1141-1152.